Article Text

other Versions

PDF
Research paper
A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK
  1. A S Carr1,
  2. A L Pelayo-Negro1,2,
  3. M RB Evans1,
  4. M Laurà1,
  5. J Blake1,3,
  6. C Stancanelli4,
  7. V Iodice4,
  8. A D Wechalekar5,
  9. C J Whelan5,
  10. J D Gilmore5,
  11. P N Hawkins5,
  12. M M Reilly1
  1. 1MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK
  2. 2Department of Neurology, University Hospital “Marqués de Valdecilla”, Santander, Spain
  3. 3Department of Clinical Neurophysiology, Norfolk and Norwich University Hospital, Norwich, UK
  4. 4Autonomic unit, National Hospital of Neurology and Neurosurgery, London, UK
  5. 5National Amyloidosis Centre, University College London Medical School, Royal Free Campus, London, UK
  1. Correspondence to Professor M M Reilly, MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, Box 108, Queen Square, London WC1N 3BG, UK; m.reilly{at}ucl.ac.uk

Abstract

Background Hereditary transthyretin amyloidosis (ATTR) is usually characterised by a progressive peripheral and autonomic neuropathy often with associated cardiac failure and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition. The UK population is unique in that the majority of patients have the T60A missense mutation in ATTR where tyrosine is replaced by adenine at position 60. This has been traced to a single founder mutation from north-west Ireland. The neuropathy phenotype is less well described than the cardiac manifestations in this group.

Methods We present the findings from an observational cohort study of patients with ATTR attending the National Hospital Inherited Neuropathy Clinic between 2009 and 2013. Detailed clinical neurological and electrophysiological data were collected on all patients alongside correlating autonomic and cardiac assessments. Follow-up data were available on a subset.

Results Forty-four patients with genetically confirmed ATTR were assessed; 37 were symptomatic; mean age at onset=62 years, range=38–75 years; 75.7% male. T60A was the most common mutation (17/37), followed by V30M (5/37). A severe, rapidly progressive, predominantly length dependent axonal sensorimotor neuropathy was the predominant phenotype. T60A patients were distinguished by earlier and more frequent association with carpal tunnel syndrome; a predominance of negative sensory symptoms at onset; significant vibration deficits; and a non-length dependent progression of motor deficit. Progression of the neuropathy was observed over a relatively short follow-up period (2 years) in 20 patients with evidence of clinically measurable annual change in Medical Research Council (MRC) sum score (–1.5 points per year) and Charcot Marie Tooth Neuropathy Score (CMTNS:2.7 points per year), and a congruent trend in the electrophysiological measures used.

Conclusion The description of the ATTR neuropathy phenotype, especially in the T60A patients, should aid early diagnosis as well as contribute to the understanding of its natural history.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.